Anavex Plus (blarcamsine/donepezil) / Anavex - LARVOL DELTA

The Role of Amyloid PET in the Management of Alzheimer's Disease (MedPageToday) - "In a study presented at the American Academy of Neurology annual meetingopens in a new tab or window, researchers evaluated the role of amyloid-beta PET scans as a diagnostic tool in clinical settings, and their influence on management with respect to Alzheimer's disease therapies....But what we did in our study was replicate what has been done at a larger scale by Gil Rabinovici, MD...which is in his case the IDEAS studyopens in a new tab or window. And what we've done is replicate that in two real-world community-based cohorts."

Video

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's Disease (GlobeNewswire) - "Top line results of randomized, placebo-controlled Phase 2b/3 study ANAVEX®2-73-AD-004 for the treatment of early Alzheimer's disease are expected in the fall of 2022...Anavex Life Sciences Corp...reported a relevant new peer-reviewed publication in the journal Science Translational Medicine...ANAVEX®2-73 activates the sigma-1 receptor (SIGMAR1). Data suggest that activation of SIGMAR1 results in the restoration of homeostatic function within the body and is pivotal to restoring neural cell balance and promoting neuroplasticity."

P2/3 data • Preclinical • Alzheimer's Disease • CNS Disorders

Anavex to present at 17th Annual BIO CEO & Investor Conference on February 10th (GlobeNewswire) - "Anavex Life Sciences...today announced that Christopher U. Missling...will present at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015 at 11:30 a.m. ET...Dr. Missling's presentation will include an overview of Anavex's advancing clinical development programs including the current Phase 2a adaptive trial evaluating ANAVEX 2-73 and ANAVEX PLUS in Alzheimer's patients."

Anticipated pipeline update • Alzheimer's Disease

Anavex confirms data from phase 2a study of ANAVEX 2-73 in Alzheimer’s patients presented at AAIC 2016 (Anavex Press Release) - "Anavex Life Sciences...confirms the information in the July 27, 2016 press release announcing positive results from the Phase 2a Alzheimer’s trial for ANAVEX 2-73. Dr. Norman Relkin, MD, PhD, an Alzheimer clinical trialist and an advisor to Anavex, commented: 'To interpret the ANAVEX 2-73 results presented at the 2016 AAIC meeting, it is important to keep in mind the stated goals of this first in Alzheimer’s patients study....The study was successful in establishing the maximum tolerated dose and in revealing the range of ANAVEX 2-73 doses that are well-tolerated by Alzheimer patients'."

Clinical • Alzheimer's Disease